 John Koeppe
Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 11 | 2014 | 2101 | 1.230 |
Why?
| | Pain | 3 | 2013 | 745 | 0.960 |
Why?
| | Analgesics | 2 | 2012 | 169 | 0.860 |
Why?
| | Analgesics, Opioid | 2 | 2013 | 599 | 0.630 |
Why?
| | Antiretroviral Therapy, Highly Active | 3 | 2012 | 245 | 0.500 |
Why?
| | Tuberculosis, Lymph Node | 1 | 2010 | 4 | 0.460 |
Why?
| | Mycobacterium avium Complex | 1 | 2010 | 72 | 0.430 |
Why?
| | Chronic Pain | 1 | 2012 | 163 | 0.410 |
Why?
| | HIV-1 | 3 | 2014 | 731 | 0.380 |
Why?
| | Viral Proteins | 2 | 2011 | 348 | 0.370 |
Why?
| | HIV Core Protein p24 | 2 | 2006 | 30 | 0.360 |
Why?
| | Delivery of Health Care | 1 | 2013 | 605 | 0.360 |
Why?
| | HIV Antigens | 1 | 2006 | 21 | 0.340 |
Why?
| | Gene Products, gag | 1 | 2006 | 37 | 0.330 |
Why?
| | Interferon-gamma | 2 | 2010 | 795 | 0.330 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2006 | 159 | 0.330 |
Why?
| | Viremia | 1 | 2006 | 111 | 0.310 |
Why?
| | Hospitalization | 1 | 2013 | 1486 | 0.310 |
Why?
| | Mycobacterium avium | 1 | 2004 | 16 | 0.290 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2004 | 22 | 0.290 |
Why?
| | Peritonitis | 1 | 2004 | 69 | 0.280 |
Why?
| | Mycobacterium avium-intracellulare Infection | 1 | 2004 | 50 | 0.270 |
Why?
| | Multivariate Analysis | 3 | 2013 | 1587 | 0.270 |
Why?
| | Emergency Service, Hospital | 1 | 2013 | 1517 | 0.260 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2006 | 996 | 0.260 |
Why?
| | Middle Aged | 12 | 2014 | 27633 | 0.190 |
Why?
| | Pain Measurement | 2 | 2012 | 544 | 0.190 |
Why?
| | Adult | 8 | 2014 | 30359 | 0.140 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2006 | 1796 | 0.140 |
Why?
| | CD4 Lymphocyte Count | 2 | 2011 | 264 | 0.140 |
Why?
| | Male | 10 | 2014 | 58392 | 0.130 |
Why?
| | Movement | 1 | 2014 | 260 | 0.120 |
Why?
| | Viral Load | 2 | 2011 | 419 | 0.120 |
Why?
| | Drug Therapy, Combination | 2 | 2006 | 995 | 0.120 |
Why?
| | Female | 9 | 2013 | 59707 | 0.120 |
Why?
| | Humans | 14 | 2014 | 104249 | 0.110 |
Why?
| | Interleukin-12 | 1 | 2010 | 107 | 0.110 |
Why?
| | Outpatients | 1 | 2011 | 191 | 0.110 |
Why?
| | Intestinal Mucosa | 1 | 2014 | 498 | 0.100 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2008 | 19 | 0.100 |
Why?
| | Severity of Illness Index | 2 | 2010 | 2653 | 0.100 |
Why?
| | Odds Ratio | 1 | 2012 | 1033 | 0.100 |
Why?
| | Cross-Sectional Studies | 2 | 2010 | 3662 | 0.100 |
Why?
| | Databases, Factual | 1 | 2013 | 1130 | 0.100 |
Why?
| | Chronic Disease | 3 | 2010 | 1686 | 0.100 |
Why?
| | Proportional Hazards Models | 1 | 2011 | 1072 | 0.100 |
Why?
| | Logistic Models | 1 | 2013 | 1984 | 0.090 |
Why?
| | HIV-Associated Lipodystrophy Syndrome | 1 | 2007 | 27 | 0.090 |
Why?
| | Leukocytes, Mononuclear | 1 | 2010 | 480 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2010 | 4685 | 0.090 |
Why?
| | Bacteria | 1 | 2014 | 648 | 0.090 |
Why?
| | HIV | 1 | 2008 | 178 | 0.090 |
Why?
| | Lipodystrophy | 1 | 2007 | 16 | 0.090 |
Why?
| | Basal Metabolism | 1 | 2007 | 72 | 0.090 |
Why?
| | Risk Factors | 2 | 2011 | 8467 | 0.090 |
Why?
| | Body Temperature Regulation | 1 | 2007 | 100 | 0.090 |
Why?
| | Retrospective Studies | 2 | 2012 | 10064 | 0.080 |
Why?
| | gag Gene Products, Human Immunodeficiency Virus | 1 | 2006 | 13 | 0.080 |
Why?
| | Glyburide | 1 | 2006 | 43 | 0.080 |
Why?
| | Patient Satisfaction | 1 | 2010 | 587 | 0.080 |
Why?
| | Caloric Restriction | 1 | 2007 | 121 | 0.080 |
Why?
| | Anti-HIV Agents | 1 | 2011 | 566 | 0.080 |
Why?
| | Socioeconomic Factors | 1 | 2010 | 1152 | 0.080 |
Why?
| | Sequence Alignment | 1 | 2006 | 372 | 0.080 |
Why?
| | Longitudinal Studies | 1 | 2012 | 2511 | 0.070 |
Why?
| | Amino Acid Sequence | 2 | 2006 | 2236 | 0.070 |
Why?
| | Treatment Outcome | 2 | 2012 | 8608 | 0.070 |
Why?
| | Lung Diseases, Interstitial | 1 | 2008 | 385 | 0.070 |
Why?
| | Immunocompetence | 1 | 2004 | 47 | 0.070 |
Why?
| | Energy Intake | 1 | 2007 | 488 | 0.070 |
Why?
| | Energy Metabolism | 2 | 2007 | 905 | 0.070 |
Why?
| | Aging | 1 | 2014 | 1668 | 0.070 |
Why?
| | Molecular Sequence Data | 2 | 2006 | 3197 | 0.070 |
Why?
| | Metformin | 1 | 2006 | 251 | 0.070 |
Why?
| | Infusions, Intravenous | 1 | 2004 | 440 | 0.070 |
Why?
| | Cohort Studies | 1 | 2011 | 4560 | 0.060 |
Why?
| | Genetic Variation | 1 | 2006 | 945 | 0.050 |
Why?
| | Hypoglycemic Agents | 1 | 2006 | 879 | 0.050 |
Why?
| | Calorimetry, Indirect | 2 | 2007 | 109 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2006 | 4339 | 0.040 |
Why?
| | Antigens, CD34 | 1 | 1996 | 94 | 0.040 |
Why?
| | Hyaluronan Receptors | 1 | 1996 | 92 | 0.040 |
Why?
| | Laryngeal Neoplasms | 1 | 1996 | 33 | 0.040 |
Why?
| | Oncogene Proteins | 1 | 1996 | 69 | 0.040 |
Why?
| | Anti-Bacterial Agents | 1 | 2004 | 1243 | 0.040 |
Why?
| | Risk Assessment | 1 | 2004 | 2934 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 1996 | 609 | 0.030 |
Why?
| | Adipose Tissue | 2 | 2007 | 625 | 0.030 |
Why?
| | Body Composition | 2 | 2007 | 709 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 1996 | 429 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 1 | 1996 | 529 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 1996 | 990 | 0.030 |
Why?
| | Erlotinib Hydrochloride | 1 | 2008 | 77 | 0.030 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2006 | 45 | 0.020 |
Why?
| | Polyurethanes | 1 | 2006 | 29 | 0.020 |
Why?
| | Quinazolines | 1 | 2008 | 231 | 0.020 |
Why?
| | Postprandial Period | 1 | 2007 | 118 | 0.020 |
Why?
| | Fluorides | 1 | 2006 | 55 | 0.020 |
Why?
| | Pulmonary Gas Exchange | 1 | 2007 | 138 | 0.020 |
Why?
| | Methacrylates | 1 | 2006 | 96 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 2862 | 0.020 |
Why?
| | Prognosis | 2 | 2008 | 3289 | 0.020 |
Why?
| | Eating | 1 | 2007 | 313 | 0.020 |
Why?
| | Triglycerides | 1 | 2007 | 540 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2008 | 528 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1433 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2014 | 2566 | 0.020 |
Why?
| | Biomarkers | 1 | 2014 | 3163 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2007 | 1580 | 0.020 |
Why?
| | Inflammation | 1 | 2014 | 2171 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2007 | 516 | 0.020 |
Why?
| | Phylogeny | 1 | 2006 | 757 | 0.020 |
Why?
| | RNA, Viral | 1 | 2006 | 562 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2008 | 802 | 0.020 |
Why?
| | Disease Progression | 1 | 2006 | 2341 | 0.010 |
Why?
| | Body Mass Index | 1 | 2007 | 2001 | 0.010 |
Why?
| | Young Adult | 1 | 2014 | 10261 | 0.010 |
Why?
| | Mutation | 1 | 2008 | 3174 | 0.010 |
Why?
| | Larynx | 1 | 1996 | 44 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1996 | 170 | 0.010 |
Why?
| | Adolescent | 1 | 2014 | 17541 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 1996 | 345 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 1996 | 1208 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 1996 | 1854 | 0.010 |
Why?
| | Gene Expression | 1 | 1996 | 1525 | 0.010 |
Why?
| | Apoptosis | 1 | 1996 | 2551 | 0.010 |
Why?
| | Prospective Studies | 1 | 1996 | 5605 | 0.000 |
Why?
| | Aged, 80 and over | 1 | 1996 | 6518 | 0.000 |
Why?
| | Aged | 1 | 1996 | 18934 | 0.000 |
Why?
|
|
Koeppe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|